<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TEGASEROD MESYLATE</span><br/>(teg-a-se'rod mes'y-late)<br/><span class="topboxtradename">Zelnorm<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">serotonin 5-<small>HT</small>
<sub>4</sub> receptor agonist</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg, 6 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>A serotonin 5-HT<sub>4</sub> receptor agonist that triggers the peristaltic reflex by activating 5-HT<sub>4</sub> receptors thereby normalizing impaired GI motility.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Significantly decreases gastric lag time, accelerates gastric emptying, reduces small bowel transit time and accelerates colonic
         transit time; thus, it increases the number of bowel movements and facilitates stool formation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short term treatment of irritable bowel syndrome (IBS) in women whose primary symptom is constipation, chronic idiopathic
         constipation in males and females 
      </p><h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>IBS in men; diabetic gastroparesis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to tegaserod; severe hepatic or renal dysfunction; cirrhosis; renal failure; bowel obstruction; symptomatic
         gall bladder disease, abdominal pain, colitis, GI bleeding; renal failure; syncope; hypotension; patients who are currently
         or frequently experiencing diarrhea; lactation; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Mild to moderate hepatic and renal impairment; MI, cardiac disease; history of ovarian cysts; patients in whom increased diarrhea
         could have negative effects; pregnancy (category B).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Irritable Bowel Syndrome</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 6 mg b.i.d. before meals for 46 wk. May extend therapy an additional 46 wk if needed and responding.<br/><br/><span class="indicationtitle">Chronic Constipation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 26 mg b.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give drug just prior to a meal with a full glass of water.</li>
<li>Determine duration of therapy prior to drug administration as manufacturer states maximum duration of therapy should be 12
            wk.
         </li>
<li>Do not initiate therapy with patients experiencing frequent diarrhea. Report to physician.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Leg pain.  <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> dizziness, migraine. <span class="typehead">GI:</span>
<span class="speceff-common">Abdominal pain,</span> diarrhea, nausea, flatulence. <span class="typehead">Musculoskeletal:</span> Back pain, arthropathy. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Food:</span> Food significantly decreases the bioavailability of tegaserod. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly absorbed, 10% bioavailability on an empty stomach. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Distribution:</span> 99% protein bound to alpha-1 glycoprotein. <span class="typehead">Metabolism:</span> Presystemic hydrolysis in stomach to an inactive metabolite. Glucuronidation in liver of remaining drug. <span class="typehead">Elimination:</span> <small>2/3</small> excreted in feces, <small>1/3</small> excreted in urine. <span class="typehead">Half-Life:</span> 11 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor baseline and periodic LFTs and renal functions.</li>
<li>Monitor symptom relief. Report lack of symptom relief or frequent diarrhea.</li>
<li>Monitor cardiovascular status especially with preexisting CV disease.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report no relief of symptoms after 4 wk of therapy as manufacturer recommends discontinuation of therapy in this case.</li>
<li>Do not breast feed while taking this drug.</li>
<li>Notify physician if you experience new or worsening abdominal pain unlike your typical IBS symptoms.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>